MedRx : H1 FY2022 Business Highlight & Financial Results

1

MEDRx (TSE:4586)

H1 FY2022 Business Highlight &

Financial Results

August 30, 2022

These materials are distributed directly by MEDRx Co., Ltd. and are available only through direct distribution. MEDRx retains all copyrights to these materials. These materials may not be copied or reused in any other way, electronically or mechanically, for any purpose without prior consent. Moreover, these materials were prepared based on the plans of MEDRx at the time of disclosure. Actual results may differ from the statements in these materials.

2

Disclaimer and Precautions

• These materials were prepared for the purpose of providing information to assist in making investment decisions. This is not a solicitation to purchase securities issued by MEDRx Co.,Ltd.
• These materials were checked carefully for accuracy, but the completeness of these materials cannot be guaranteed. MEDRx does not accept any responsibility for any problems or damages that result from the information provided in these materials.
• These materials contain forward-looking statements that include estimates, expectations or risks at the time these materials were created. Actual results may differ from these forecasts due to uncertainties such as overall industry and market trends, interest rates and foreign exchange fluctuations, and other economic factors in Japan and overseas.
• MEDRx is not obligated to update or revise the forward-looking statements in these materials even in the event of new information or future events.

These materials are distributed directly by MEDRx Co., Ltd. and are available only through direct distribution. MEDRx retains all copyrights to these materials. These materials may not be copied or reused in any other way, electronically or mechanically, for any purpose without prior consent. Moreover, these materials were prepared based on the plans of MEDRx at the time of disclosure. Actual results may differ from the statements in these materials.

Three Core Transdermal Drug Delivery Platforms

3

Ionic Liquid	Nano-sizedColloid	Microneedle
Transdermal System	Transdermal System	(MN)

These materials are distributed directly by MEDRx Co., Ltd. and are available only through direct distribution. MEDRx retains all copyrights to these materials. These materials may not be

copied or reused in any other way, electronically or mechanically, for any purpose without prior consent. Moreover, these materials were preparedCo, ltdbased. All rightson thereservedplans of MEDRx at the time 3of disclosure. Actual results may differ from the statements in these materials.

4

Pipeline : "Primary Target is US market"

Product name	Drug Formulation	Pre	Ph-Ⅰ	Ph-Ⅱ		Ph-Ⅲ		NDA		Launch
Development Code	Development	Clinical
CPN-101(MRX-4TZT)				Worldwide licensing agreement (except for
			East Asia) with Cipla USA Inc.
Spasticity				Phase 1b has got successful result.
(Tizanidine, transdermal, ILTS®)				Phase 2 to be prepared

MRX-5LBT "Lydolyte"
	Receipt of Complete Response Letter
Neuropathic Pain		Expected to get approval in 2023 after additional study
(Lidocaine, topical, ILTS®)
MRX-9FLT
				Fast Track designation
Moderate-Severe Pain
				Clinical Study on-going
(Fentanyl, transdermal, ILTS®)
MRX-1OXT
				Phase 1a has got result
Moderate-Severe Pain
(Oxycodone, transdermal, ILTS®)
MRX-7MLL
Alzheimer's Disease			IND filing
(Memantine, transdermal, NCTS®)
MRX-6LDT
Chronic Pain
(Diclofenac-lidocaine, ILTS®)

5

Pipeline : "Primary Target is US market"

Product name	Drug Formulation	Pre	Ph-Ⅰ	Ph-Ⅱ		Ph-Ⅲ		NDA		Launch
Development Code	Development	Clinical
CPN-101(MRX-4TZT)				Worldwide licensing agreement (except for
			East Asia) with Cipla USA Inc.
Spasticity				Phase 1b has got successful result.
(Tizanidine, transdermal, ILTS®)				Phase 2 to be prepared

MRX-5LBT "Lydolyte"
	Receipt of Complete Response Letter
Neuropathic Pain		Expected to get approval in 2023 after additional study
(Lidocaine, topical, ILTS®)
MRX-9FLT
				Fast Track designation
Moderate-Severe Pain
				Clinical Study on-going
(Fentanyl, transdermal, ILTS®)
MRX-1OXT
				Phase 1a has got result
Moderate-Severe Pain
(Oxycodone, transdermal, ILTS®)
MRX-7MLL
Alzheimer's Disease			IND filing
(Memantine, transdermal, NCTS®)
MRX-6LDT
Chronic Pain
(Diclofenac-lidocaine, ILTS®)